Pluvicto
CMS Rolling Out New Payment Policy for High-Cost Diagnostic Radiopharmaceuticals
The government payor said it will separately pay for specialized diagnostic radiopharmaceuticals without transitional pass-through payment status.
Novartis Sees Steady Q3 Pluvicto Sales Growth as it Readies to Triple Eligible Population in 2025
Premium
The Swiss drugmaker is gearing up to meet a surge in patient demand for the radiopharmaceutical if the FDA approves it in an earlier-line prostate cancer setting.
Telix Files for FDA Approval for New PSMA-PET Imaging Agent TLX007-CDx
The firm already markets a radiopharmaceutical companion diagnostic for Pluvicto but is hoping to improve patient access with this new imaging agent.
Growth of the prostate cancer radiopharmaceutical was exponential following approval, but has now settled, leading Novartis to ramp up promotional efforts.
The drugmaker will seek regulatory approval for Scemblix in first-line Ph-positive CML and other precision drugs in the coming months.